Biokine
Therapeutics begun a Phase I/IIa study of
BKT140, a myeloma treatment, at Chaim Sheba Medical Center in Tel-Hasomer, Israel, after receiving a $1.2 million grant from the office of the chief scientist of the Israeli ministry of industry, trade and labor.
The firm says that in experimental models, BKT140 promoted normal cell production in bone marrow and their entry into the blood while initiating death and removal of myeloma and leukemia cells.
Biokine, founded in 2000 in Israel, focuses on the development of pharmaceuticals that control the activity of receptors for the chemokine CXCR4.